Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma

Απλή σελίδα τεκμηρίου
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T18:54:51Z
dc.date.available2015-11-24T18:54:51Z
dc.identifier.issn0277-3732-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18758
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBleomycin/administration & dosage/adverse effectsen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInterferon-alpha/administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMelanoma/*drug therapy/pathology/secondaryen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectRecombinant Proteinsen
dc.subjectVinblastine/administration & dosage/adverse effectsen
dc.titleRecombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanomaen
heal.abstractThirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN for 1 year or until progression. Of the 34 analyzed patients, 17 (50%) achieved an objective response, including two complete (6%) and 15 partial responses (44%). Responses were noted in cutaneous, lymph node, and pulmonary sites, with a median time to disease progression of 5 months (range, 3-20 months). The median survival from onset of therapy was 8 months (range, 1-22 months) for the 34 patients. Ninety-four percent of the patients experienced flu-like symptoms and 82% fatigue or weakness. Leukopenia grade 3-4 was observed in four patients (12%). There were two toxicity-related deaths (6%); one from bleomycin-induced pneumonitis and one from neutropenic sepsis. It is concluded that the addition of IFN to CVB regimen, in this study, showed no apparent advantage on response rates, disease-free interval, or survival. The observed treatment-related mortality was unacceptably high. IFN administered as maintenance therapy following CVB conferred no survival benefit.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8638545-
heal.journalNameAm J Clin Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ